San Francisco, California, July 19, 2017: TMR Research announces a new report on the global gram-negative bacterial infection market. The report provides readers with a clear picture of the historical development trajectory of the global gram-negative bacterial infection market by profiling the growth of key segments of the market. The competitive dynamics of the gram-negative bacterial infection market are also studied in the report, making it a comprehensive must-have accessory for interested parties in the market. The report is titled ‘Gram-Negative Bacterial Infection Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025.’
Gram-negative bacteria constitute a major health threat in several parts of the world due to the severity and diversity of diseases they can cause. The increasing attention being paid to the healthcare sector in several countries is thus likely to be a key driver for the global gram-negative bacterial infection market.
By type of infection, the global gram-negative bacterial infection market is segmented into pneumonia, bloodstream infections, meningitis, urinary tract infections, and surgical site infections. Pneumonia treatment is likely to remain a key revenue channel for the global gram-negative bacterial infection market in the coming years due to the rising prevalence of the disease in emerging regions. The rising air pollution concerns in several countries are also likely to enable a rise in the prevalence of pneumonia, which will aid the gram-negative bacterial infection market’s growth.
Meningitis is also a key health concern across the world. Meningitis caused by gram-negative bacteria has a high fatality count – 25% of newborns suffering from gram-negative bacterial meningitis die, while around 20% suffer from serious nervous and other problems. The key role of gram-negative bacteria in causing meningitis is likely to keep meningitis treatment an important segment of the global gram-negative bacterial infections market.
By treatment type, the global gram-negative bacterial infection market is segmented into carbapenes, rifampin, tigecyclin, colistin, doxycycline, and sulbactam. Carbapenes are likely to dominate the global gram-negative bacterial infection market over the coming years due to their use in the treatment of pneumonia. Sulbactam is also likely to attain a significant role due to the rising prevalence of meningitis across the world. However, rifampin, tigecyclin, colistin, and doxycycline are used in the treatment of multiple gram-negative bacterial infections and are thus likely to retain key shares in the global gram-negative bacterial infections market in the coming years.
The competitive landscape of the global gram-negative bacterial infections market is examined in close detail in the report. Key gram-negative bacterial infection market players profiled in the report include Novartis AG, Baxter International Inc., Pfizer Inc., Dainippon Sumitomo Pharma Co. Ltd., GlaxoSmithKline Plc, Sanofi-Aventis, Nektar Therapeutics, Takeda Pharmaceutical Company Limited, Rib-X Pharmaceuticals Inc., and Targeted Genetics Corporation.